Acumen Pharmaceuticals (ABOS) Net Cash Flow (2020 - 2026)

Acumen Pharmaceuticals (ABOS) has 7 years of Net Cash Flow data on file, last reported at -$2.2 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow rose 59.89% year-over-year to -$2.2 million; the trailing twelve-month figure through Mar 2026 stood at $21.6 million (up 228.99% YoY), and the FY2025 full-year result was $18.4 million, up 158.74% from the prior year.
• Net Cash Flow retreated to -$2.2 million in Q1 2026, from $7.2 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $46.5 million in Q3 2022 to a low of -$52.1 million in Q1 2023.
• A 5-year average of -$4.1 million and a median of -$751000.0 in 2023 frame the typical range for Net Cash Flow.
• Across the five-year window, Net Cash Flow sank 465.32% in 2022 and jumped 2899.73% in 2024, its largest moves.
• Tracing ABOS's Net Cash Flow over 5 years: stood at -$27.4 million in 2022, then slipped by 2.0% to -$28.0 million in 2023, then soared by 108.71% to $2.4 million in 2024, then surged by 193.4% to $7.2 million in 2025, then sank by 130.65% to -$2.2 million in 2026.
• Business Quant data shows ABOS's Net Cash Flow at -$2.2 million in Q1 2026, $7.2 million in Q4 2025, and $10.0 million in Q3 2025.